Effectiveness of salivary stimulation using xylitol-malic acid tablets as coadjuvant treatment in patients with gastro-oesophageal reflux disease : early findings
NAGIOS: RODERIC FUNCIONANDO

Effectiveness of salivary stimulation using xylitol-malic acid tablets as coadjuvant treatment in patients with gastro-oesophageal reflux disease : early findings

DSpace Repository

Effectiveness of salivary stimulation using xylitol-malic acid tablets as coadjuvant treatment in patients with gastro-oesophageal reflux disease : early findings

Show simple item record

dc.contributor.author Sánchez Blanco, Irene es
dc.contributor.author Rodríguez Téllez, Manuel es
dc.contributor.author Corcuera Flores, José Ramón es
dc.contributor.author González-Blanco, Carolina es
dc.contributor.author Torres Lagares, Daniel es
dc.contributor.author Serrera Figallo, María Angeles es
dc.contributor.author Machuca-Portillo, Guillermo es
dc.date.accessioned 2021-05-04T11:01:19Z
dc.date.available 2021-05-04T11:01:19Z
dc.date.issued 2020 es
dc.identifier.uri https://hdl.handle.net/10550/79092
dc.description.abstract Besides dental erosion syndrome, other oral syndromes could benefit from the stimulation of salivary secretion, in patients with gastro-oesophageal reflux disease (GORD). Our aims is evaluate the improvement of oral extra-oesophageal manifestations in patients with GORD using xylitol?malic acid tablets to stimulate salivary secretion. The effectiveness of salivary stimulation using xylitol?malic acid tablets (as a supplement to omeprazole 40 mg/day) was assessed in a clinical trial (n = 14) lasting six months with patients with prior positive pH-metry, through GORD extra-oesophageal clinical signs, GerdQ and RDQ questionnaires, odontological variables, basal salivary secretion, stimulated salivary secretion, pH and buffer capacity, mucosal erythema index and dental wear. Statistics: chi-square (Haberman post-hoc), ANOVA, and Mann-Whitney U; variables between visits were evaluated with McNemar?s Student?s t and Wilcoxon tests; p < 0.05. 100% of patients not taking xylitol?malic acid presented xerostomia, but only 14.3% of patients taking xylitol?malic acid (p < 0.01) did. The mean saliva-buffer capacity at the last visit for patients not taking xylitol?malic acid was 2.14 ± 0.38, versus 2.71 ± 0.49 for patients taking xylitol?malic acid (p < 0.05). Retro-sternal burning (p < 0.05), heartburn (p < 0.05) and regurgitation (p < 0.05) were also reduced. Xylitol?malic acid tablets improve quality of life among patients with GORD, by reducing dry mouth, increasing saliva buffering and reducing heartburn, retro-sternal burning and regurgitation. es
dc.source Sánchez Blanco, Irene ; Rodríguez Téllez, Manuel ; Corcuera Flores, José Ramón ; González-Blanco, Carolina ; Torres Lagares, Daniel ; Serrera Figallo, María Angeles ; Machuca-Portillo, Guillermo. Effectiveness of salivary stimulation using xylitol-malic acid tablets as coadjuvant treatment in patients with gastro-oesophageal reflux disease : early findings. En: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, 25 6 2020: 18- es
dc.title Effectiveness of salivary stimulation using xylitol-malic acid tablets as coadjuvant treatment in patients with gastro-oesophageal reflux disease : early findings es
dc.type info:eu-repo/semantics/article en
dc.type info:eu-repo/semantics/publishedVersion en
dc.subject.unesco UNESCO::CIENCIAS MÉDICAS es
dc.identifier.doi 10.4317/medoral.23887 es

View       (542.3Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics